Finance

Lists
Why is ALKS down 2,69%?
Dive Deeper
ALKS:NASDAQ
Alkermes Plc
44,94 $
-2,69%
(-1,24) 1D
45,50 $
+1,25% (+0,56)
After hours
Closed: 20 қар., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALKS...
Open
45,79 $
High
46,89 $
Low
44,83 $
Mkt. cap
7,55 млрд
Avg. vol.
1,71 млн
Volume
1,08 млн
52-wk high
55,67 $
52-wk low
27,00 $
EPS
-0,01 $
Beta
0,29
Shares outstanding
168,04 млн
No. of employees
2 мың
Open
45,79 $
High
46,89 $
Low
44,83 $
Mkt. cap
7,55 млрд
Avg. vol.
1,71 млн
Volume
1,08 млн
52-wk high
55,67 $
52-wk low
27,00 $
EPS
-0,01 $
Beta
0,29
Shares outstanding
168,04 млн
No. of employees
2 мың
News stories
From web sources and news partners
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2,05 мың
Founded1987
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 13 analysts giving stock ratings to ALKS in the past 3 months
Buy
Buy
9
Hold
3
Sell
1
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ALKS in the last 3 months.
Highest
Current 44,94 $
83,00 $ (+84,69%)
Average
61,73 $ (+37,36%)
Lowest
50,00 $ (+11,26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Buy
Maintained
57,00 $
+26,8%
11/12/2026
Jason Gerberry
Bank of America Securities
Sell
Reiterated
-
-
11/04/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
68,00 $
+51,3%
11/03/2026
Douglas Tsao
H.C. Wainwright
Hold
Maintained
50,00 $
+11,3%
11/04/2026
Ami Fadia
Needham
Buy
Reiterated
62,00 $
+38%
10/19/2026
David Amsellem
Piper Sandler
Buy
Reiterated
65,00 $
+44,6%
10/19/2026
Alex Nackenoff
Truist Financial
Buy
Initiated
55,00 $
+22,4%
10/16/2026
Unknown Analyst
Truist Financial
Buy
Initiated
55,00 $
+22,4%
10/16/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
63,00 $
+40,2%
10/05/2026
Andrea Newkirk
Goldman Sachs
Hold
Initiated
50,00 $
+11,3%
09/24/2026
Akash Tewari
Jefferies
Buy
Maintained
83,00 $
+84,7%
09/22/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
-
-
09/21/2026
Luke Herrmann
Robert W. Baird
Buy
Maintained
61,00 $
+35,7%
09/22/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
65,00 $
+44,6%
09/22/2026
Uy Ear
Mizuho Securities
Buy
Maintained
65,00 $
+44,6%
09/04/2026
Joseph Thome
TD Cowen
Buy
Maintained
58,00 $
+29,1%
07/28/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
44,00 $
-2,1%
05/13/2026
Ashwani Verma
UBS
Buy
Maintained
48,00 $
+6,8%
05/06/2026
Marc Goodman
Leerink Partners
Hold
Maintained
-
-
03/31/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
43,00 $
-4,3%
03/11/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
02/26/2026
Rudy Li
Wolfe Research
Buy
Initiated
45,00 $
+0,1%
02/23/2026
Last report
2026 ж. 03 қар.
Fiscal period
Q3 2026
0,57 $ / 0,25 $
+130,87%beat
Revenue / Est. (USD)
480,13 млн / 463,48 млн
+3,59%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
2026 ж. қыр.
Revenue
384,55 млн
392,91 млн
496,01 млн
480,13 млн
Cost of goods sold
46,21 млн
48,85 млн
67,11 млн
65,52 млн
Cost of revenue
46,21 млн
48,85 млн
67,11 млн
65,52 млн
Research and development expenses
89,73 млн
100,08 млн
109,58 млн
117,76 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
190,50 млн
233,06 млн
219,86 млн
210,36 млн
Operating expense
280,23 млн
344,81 млн
352,03 млн
347,82 млн
Total operating expenses
326,44 млн
393,66 млн
419,14 млн
413,34 млн
Operating income
58,10 млн
-754,00 м.
76,87 млн
66,79 млн
Other non operating income
1,42 млн
-1,29 млн
852,00 м.
-223,00 м.
EBT including unusual items
60,38 млн
-61,93 млн
-1,88 млн
14,74 млн
EBT excluding unusual items
60,38 млн
-14,40 млн
57,14 млн
45,50 млн
Income tax expense
11,04 млн
4,55 млн
-2,38 млн
-1,55 млн
Effective tax rate
18,28%
-7,35%
126,71%
-10,52%
Other operating expenses
-
-
-
-
Net income
49,34 млн
-66,48 млн
501,00 м.
16,29 млн
Net profit margin
12,83%
-16,92%
0,10%
3,39%
Earnings per share
0,48
0,38
0,70
0,57
Interest and investment income
12,13 млн
8,54 млн
5,34 млн
6,49 млн
Interest expense
-12,28 млн
-20,89 млн
-25,92 млн
-27,55 млн
Net interest expenses
-147,00 м.
-12,35 млн
-20,58 млн
-21,06 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
61,95 млн
18,68 млн
107,14 млн
93,95 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google қолданбалары